Pain in sickle cell disease: A multidimensional construct

Renaissance of Sickle Cell Disease Research in the Genome Era

Volumn , Issue , 2007, Pages 99-116

  Benjamin, Lennette J ^a   Payne, Richard ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84967520835     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781860947964_0007     Document Type: Chapter

References (78)

1. US Department of Health and Human Services, National Institute of Health, National Heart, Lung, and Blood Institute, Division of Blood Diseases and Resources (2002). The Management of Sickle Cell Disease, 4th edition. NIH Publication, No. 02-2117.
2. Benjamin LJ, Dampier CD, Jacox AK et al. (1999). Guideline for the Management of Acute and Chronic Pain in Sickle-Cell Disease, APS Clinical Practice Guidelines Series No 1. Glenview, IL.
3. Payne, R (1997). Pain management in sickle cell anemia. Anesth Clin N Am 15:306-318.
4. Gil KM, Porter L, Ready J et al. (2000). Pain in children and adolescents with sickle cell disease: an analysis of daily pain diary. Children’s Health Care 29:225-241.
5. Dampier C, Ely B, Brodericki D, O’Neal P (2002). Characteristics of pain managed at home in children and adolescents with sickle cell disease by using diary self-reports. J Pain 3:461-470.
6. Platt OS, Brambilla DJ, Rosse WF et al. (1994). Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330:1639-1644.
7. Stuart MJ, Nagel RL (2004). Sickle Cell Disease. Lancet 364(9442):1343-1360.
8. Harrison OM, Edwards CL, Koenig HG et al. (2005). Religiosity/Spirituality and pain in patients with sickle cell disease. J Nerv Mental Dis 193(4):250-257.
9. Ballas SK (1998). Sickle cell pain. In: Progress in Pain Research and Management, Vol. 11. Seattle, WA: IASP Press.
10. Benjamin LJ (2001). The nature and management of acute painful episode in sickle cell disease. In: Forget BG, Higgs D, Nagel RL, Steinberg MH, editors. Disorders of Hemoglobin. Cambridge, UK: Cambridge University Press, pp. 671-710.
11. Hebbel RP, Osarogiagbon R, Kaul D (2004). The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 11(2):129-151.
12. Bonds DR (2005). Three decades of innovation in the management of sickle cell disease: the road to understanding the sickle cell disease clinical phenotype. Blood Rev 19:99-110.
13. Platt OS, Thorington BD, Brambilla DJ et al. (1991). Pain in sickle-cell disease: rates and risk factors. New Engl J Med 325:11-16.
14. Charache S, Terrin ML, Moore Rd et al. (1995). Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 332:1317-1322.
15. Miller ST, Sleeper LA, Pegelow CH et al. (2000). Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 342(2):83-89.
16. Steinberg MH, Hsu H, Nagel RL et al. (1995). Gender and haplotype: effects upon hematological manifestations of adult sickle cell anemia: effects of haplotype in sickle cell anemia. Am J Hematol 48:175-181.
17. Powars DR et al. (1994). Beta-S gene cluster haplotypes modulate hematologic and hemorrheologic expression in sickle cell anemia. Use in predicting clinical severity. Am J Pediatr Hematol Oncol 16:55-61.
18. Alexander N, Higgs D, Dover G, Sergeant GR (2004). Are there clinical phenotypes of homozygous sickle cell disease? Br J Haematol 126(4):606-611.
19. Gil KM, Carson JW, Porter LS et al. (2004). Daily mood and stress predict pain, health care use and work activity in African American adults with sickle cell disease. Health Psychol 23(3):267-274.
20. Niv D, Dvor M (1998). Transition from acute to chronic pain. In: Arnoff GM, editor. Evaluation and Treatment of Chronic Pain, 3rd edition. Baltimore: Williams and Wilkins.
21. Eap CB, Budin T, Bauman P (2002). Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 41:1153-1193.
22. Scholz J, Woolf CJ (2002). Can we conquer pain? Nat Neurosci 5(Suppl): 1062-1067.
23. Sabino MA, Mantyh PW (2005). Pathophysiology of bone cancer pain. J Support Oncol 3(1):15-24.
24. Julius D, Basbaum AI (2001). Molecular mechanisms of nociception. Nature 413(6852):203-210.
25. Watkins LR, Maier SF (2000). The pain of being sick: implications of immune-to-brain communications for understanding pain. Ann Rev Psychol 51:29-57.
26. Mankad VN, Williams JP, Harpen MD et al. (1990). Magnetic resonance imaging of bone marrow in sickle cell disease: clinical, hematologic, and pathologic correlations. Blood 75(1):274-220.
27. Kim SK, Miller JH (2002). Natural history and distribution of bone and bone marrow infarction in sickle hemoglobinopathies. J Nucl Med 43(7):896-900.
28. Kavadia-Tsatala S, Kolokytha O, Kaklamanos EG, Antoniades K, Chasapopoulou E (2004). Mandibular lesions of vasocclusive origin in sickle cell hemoglobinopathy. Odontology 92(1):68-72.
29. Yaster M, Byerly S, Maxwell L (2000). The management of pain in sickle cell disease. Pedia Clin North Am 47:699-710.
30. Fuggle P, Shand PA, Gill LJ, Davies SC (1996). Pain, quality of life, and coping in sickle cell disease. Archives of Diseases in Childhood 75:199-203.
31. Zubieta J-K, Heitzeg MM, Smith, YR et al. (2003). COMT val158met genotype affects u-opioid neurotransmitter responses to a pain stressor. Science 299:1240-1244.
32. Coda BA, Bonica JJ (2001). General considerations of acute pain. In: Loeser JD, Butler SH, Chapman CR, Turk DC, editors. Bonica’s Management of Pain. Philadelphia: Lippincott Williams & Wilkins, Ch. 9, pp. 222-240.
33. Jambrik Z, Santarcangelo EL, Rudisch T, Varga A et al. (2005). Modulation of pain-induced endothelial dysfunction by hypnotisability. Pain 116:181-186.
34. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL (2000). Defining the clinically important difference in pain outcome measures. Pain 88:287-294.
35. Fishman B, Pasternak S, Wallenstein SL et al. (1987). The Memorial Pain Assessment Card: a valid instrument for the evaluation of cancer pain. Cancer 60:1151-1158.
36. Beyer JE, Simmons LE (2004). Home treatment of pain for children and adolescentswith sickle cell disease. Pain Manage Nurs 5(3):126-135.
37. Backonia MM, Stacey B (2004). Neuropathic pain symptoms relative to overall pain rating. J Pain 5: 491-497.
38. Benjamin W, Swinson GI, Nagel R (2000). Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crisis. Blood 95:1130-1137.
39. Ware M, Hambleton I, Ochaya I, Sergeant GR (1999). Day care management of sickle cell painful crisis in Jamaica: a model applicable elsewhere? Br J Haematol 104:93-96.
40. Dampier C, Ely B, Broderick D et al. (2004). Vaso-Occlusion in children with sickle cell disease: clinical characteristics and biologic correlates. J Pediatr Hematol/Oncol 26(12):785-790.
41. Wright J, Bareford D, Wright C et al. (2004). Day case management of sickle pain: 3 years experience in a UK sickle cell unit. Br J Haematol 126(6):878-880.
42. Rees DC, Olujohungbe AD, Parker NE et al. (2003). Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol 120(5):744-752.
43. Marlone KF, Chicella MF (2002). Treatment of sickle cell pain. Pharmacotherapy 22(4):484-491.
44. Bruera E, Pereira J (1997). Neuropsychiatric toxicity of opioids. In: Jensen TS, Turner JA, Wissenfeld-Hallin Z, editors. Proceedings of the Eighth World Congress on Pain, Vol. 8.
45. Rouse CM (2004). Paradigms and politics: shaping health care access for sickle cell patients through the discursive regimes of biomedicine. Cult Med Psychiatry 28(3):369-399.
46. Bonham VL (2001). Race, ethnicity, and pain treatment: striving to understand the causes and solutions to the disparities in pain treatment. J Law Med Ethics 29:52-68.
47. Morrison RS, Wallenstein S, Natale D, Senzel RS, Huang LL (2000). “We don’t carry that” - failure of pharmacies in predominantly nonwhite neighborhoods to stock opioid analgesics. N Engl J Med 342: 1023-1026.
48. Armstrong ED, Pegelow CH, Gonzalez JC, Martinez A (1995). Impact of children’s sickle cell history on nurse and physician ratings of pain and medication decisions. J Pediatric Psychol 71:651-664.
49. Melzack R (1990). The tragedy of needless pain. Sci Am 262(2):27-33.
50. Pasero C, Paice JA, McCaffery M (1999). Basic mechanism underlying the causes and effects of pain. In: McCaffery M, Pasero C, editors. Clinical Manual. Mosby, Inc., pp. 15-34.
51. Cervero F, Laird JMA (1996). Mechanisms of touch-evoked pain (allodynia): a new model. Pain 68:13-23.
52. Wolff CJ, Salter MW (2000). Neuronal plasticity: increasing the gain in pain. Science 288:1765-1769f.
53. Marks RM, Sacher EJ (1973). Undertreatment of medical inpatients with narcotic analgesics. Ann Intern Med 78:173-181.
54. Bennett P, St. Marie B (2002). The Epidemiology of Pain, Core Curriculum for Pain Management Nursing. Philadelphia: W.B. Saunders Company, pp. 45-53.
55. Weissman DE, Haddox JD (1989). Opioid pseudo-addiction: an iatrogenic syndrome. Pain 36:363-366.
56. Elander J, Lusher J, Bevan D, Telfer P, Burton (2004). Understanding the causes of problematic pain management in sickle cell disease: evidence that pseudoaddiction plays a more important role than genuine analgesic dependence. J Pain Symptom Manage 27(2):156-169.
57. Mercante S, Ferraera P, Villari P, Arcuri E (2003). Hyperalgesia: an emerging Iatrogenic syndrome. J Pain Symptom Manage 26:769-775.
58. Mao J, Sung B, Ji RR, Lim G (2002). Chronic morphine indices down regulation of spinal glutamate transporters: implication in morphine tolerance and abnormal pain sensitivity. J Neurosci 22(18): 8312-8323.
59. Ballantyne JC, Mao J (2003). Opioid therapy for chronic pain. N Engl J Med 349(20):1943-1953.
60. Mayer DJ, Mao J, Holt J, Price DD (1999). Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc Natl Acad Sci USA 96:7731-7736.
61. Elliott K, Kest B, Inturrisi CE (1995). NMDA receptors, mu and kappa opioid tolerance and perspectives on new drug development. Neuropsychopharmacology 13:347-356.
62. Nagar S, Remmel RP, Hebbel RP, Zimmerman CL (2004). Metabolism of opioids is altered in liver microsome of sickle cell transgenic mice. Drug Metab Dispos 32(1): 98-104.
63. Kreek MJ (1992). Rationale for maintenance pharmacotherapy of opiate dependence. In: O’Brien CP, Jaffe JH, editors. Addictive States. New York: Raven Press, pp. 205-230.
64. Kreek MJ (1996). Opiates, opioids and addiction. Mol Psych 1:232-254.
65. Compton P, Athanasos P, Elashoff D (2003). Withdrawal hyperalgesia after acute opioid physical dependence in nonaddicted humans: a preliminary study. J Pain 4:11-519
66. Linklater DR, Pemberton L, Taylor S, Zeger W (2005). Painful dilemmas: an evidence-based look at challenging clinical scenarios. Emerg Med Clin North Am 23(2):367-392.
67. Ballas SK, Lusardi M (2005). Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol 79(1):17-25.
68. Mao J (2002). Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 100:213-217.
69. Rapamonti C, Dickerson ED (2001). Strategies for the treatment of cancer pain in the new millennium. Drugs 61(7):955-977.
70. Manfredi PL, Houde RW (2003). Prescribing methadone: a unique analgesic. J Support Oncol 1:216-220.
71. Rosen SH, Zeldin G, Davidson EM (2001). Methadone is safe for treatment of hospitalized patients with severe pain. Can J Anest 48(11):1109.
72. Davis AM, Inturrisi CE (1999). d-Methadone blocks morphine tolerance and N-methyl-D-aspartate (NMDA)-induced hyperalgesia. J Pharmacol Exp Ther 289:1048-1053.
73. US Dept HHS (2004). Methadone-Associated Mortality: Report of a National Assessment.
74. Foley KM, Houde RW (1998). Methadone and cancer pain management: individualize dose and titrate to effect. J Clin Oncol 16:3213-3215.
75. Kornick CA, Kilborn MJ, Santiago-Palma J et al. (2003). QTc interval prolongation associated with intravenous methadone. Pain 105:499-506.
76. Porter BO, Coyne PJ, Smith WR (2005). Methadone-related Torsades de Pointes in a sickle cell patient treated for chronic pain. Am J Hematol 78:316-319.
77. Cruciani RA, Sekine R, Homel P, Lussier D et al. (2005). Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage 29:385-391.
78. Lippe PM (2000). The decade of pain control and research. Pain Med 1(4):286-289.